120 related articles for article (PubMed ID: 10350482)
1. A single amino acid residue contributes to distinct mechanisms of inhibition of the human multidrug transporter by stereoisomers of the dopamine receptor antagonist flupentixol.
Dey S; Hafkemeyer P; Pastan I; Gottesman MM
Biochemistry; 1999 May; 38(20):6630-9. PubMed ID: 10350482
[TBL] [Abstract][Full Text] [Related]
2. Modulator-induced interference in functional cross talk between the substrate and the ATP sites of human P-glycoprotein.
Maki N; Moitra K; Silver C; Ghosh P; Chattopadhyay A; Dey S
Biochemistry; 2006 Feb; 45(8):2739-51. PubMed ID: 16489767
[TBL] [Abstract][Full Text] [Related]
3. Biochemical and pharmacological properties of an allosteric modulator site of the human P-glycoprotein (ABCB1).
Maki N; Dey S
Biochem Pharmacol; 2006 Jul; 72(2):145-55. PubMed ID: 16729976
[TBL] [Abstract][Full Text] [Related]
4. Structural flexibility of the linker region of human P-glycoprotein permits ATP hydrolysis and drug transport.
Hrycyna CA; Airan LE; Germann UA; Ambudkar SV; Pastan I; Gottesman MM
Biochemistry; 1998 Sep; 37(39):13660-73. PubMed ID: 9753453
[TBL] [Abstract][Full Text] [Related]
5. Biochemical basis of polyvalency as a strategy for enhancing the efficacy of P-glycoprotein (ABCB1) modulators: stipiamide homodimers separated with defined-length spacers reverse drug efflux with greater efficacy.
Sauna ZE; Andrus MB; Turner TM; Ambudkar SV
Biochemistry; 2004 Mar; 43(8):2262-71. PubMed ID: 14979722
[TBL] [Abstract][Full Text] [Related]
6. Allosteric modulation of the human P-glycoprotein involves conformational changes mimicking catalytic transition intermediates.
Ghosh P; Moitra K; Maki N; Dey S
Arch Biochem Biophys; 2006 Jun; 450(1):100-12. PubMed ID: 16624245
[TBL] [Abstract][Full Text] [Related]
7. Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein.
Dey S; Ramachandra M; Pastan I; Gottesman MM; Ambudkar SV
Proc Natl Acad Sci U S A; 1997 Sep; 94(20):10594-9. PubMed ID: 9380680
[TBL] [Abstract][Full Text] [Related]
8. Contribution to substrate specificity and transport of nonconserved residues in transmembrane domain 12 of human P-glycoprotein.
Hafkemeyer P; Dey S; Ambudkar SV; Hrycyna CA; Pastan I; Gottesman MM
Biochemistry; 1998 Nov; 37(46):16400-9. PubMed ID: 9819232
[TBL] [Abstract][Full Text] [Related]
9. Allosteric modulation bypasses the requirement for ATP hydrolysis in regenerating low affinity transition state conformation of human P-glycoprotein.
Maki N; Moitra K; Ghosh P; Dey S
J Biol Chem; 2006 Apr; 281(16):10769-77. PubMed ID: 16505485
[TBL] [Abstract][Full Text] [Related]
10. Allosteric modulation of human P-glycoprotein. Inhibition of transport by preventing substrate translocation and dissociation.
Maki N; Hafkemeyer P; Dey S
J Biol Chem; 2003 May; 278(20):18132-9. PubMed ID: 12642584
[TBL] [Abstract][Full Text] [Related]
11. Gomisin A alters substrate interaction and reverses P-glycoprotein-mediated multidrug resistance in HepG2-DR cells.
Wan CK; Zhu GY; Shen XL; Chattopadhyay A; Dey S; Fong WF
Biochem Pharmacol; 2006 Sep; 72(7):824-37. PubMed ID: 16889754
[TBL] [Abstract][Full Text] [Related]
12. Both ATP sites of human P-glycoprotein are essential but not symmetric.
Hrycyna CA; Ramachandra M; Germann UA; Cheng PW; Pastan I; Gottesman MM
Biochemistry; 1999 Oct; 38(42):13887-99. PubMed ID: 10529234
[TBL] [Abstract][Full Text] [Related]
13. Analysis of random recombination between human MDR1 and mouse mdr1a cDNA in a pHaMDR-dihydrofolate reductase bicistronic expression system.
Shoshani T; Zhang S; Dey S; Pastan I; Gottesman MM
Mol Pharmacol; 1998 Oct; 54(4):623-30. PubMed ID: 9765504
[TBL] [Abstract][Full Text] [Related]
14. Drug binding and nucleotide hydrolyzability are essential requirements in the vanadate-induced inhibition of the human P-glycoprotein ATPase.
Rao US
Biochemistry; 1998 Oct; 37(42):14981-8. PubMed ID: 9778376
[TBL] [Abstract][Full Text] [Related]
15. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter.
Lee CG; Gottesman MM; Cardarelli CO; Ramachandra M; Jeang KT; Ambudkar SV; Pastan I; Dey S
Biochemistry; 1998 Mar; 37(11):3594-601. PubMed ID: 9530286
[TBL] [Abstract][Full Text] [Related]
16. Bivalent probes of the human multidrug transporter P-glycoprotein.
Pires MM; Hrycyna CA; Chmielewski J
Biochemistry; 2006 Sep; 45(38):11695-702. PubMed ID: 16981729
[TBL] [Abstract][Full Text] [Related]
17. N-ethylmaleimide increases P-glycoprotein photoaffinity labeling with iodoaryl-azidoprazosin in multidrug resistant cells.
Wang Y; Georges E
Anticancer Res; 1997; 17(1A):357-64. PubMed ID: 9066677
[TBL] [Abstract][Full Text] [Related]
18. Further characterization of the sixth transmembrane domain of Pgp1 by site-directed mutagenesis.
Song J; Melera PW
Cancer Chemother Pharmacol; 2001 Nov; 48(5):339-46. PubMed ID: 11761450
[TBL] [Abstract][Full Text] [Related]
19. Evidence for modulatory sites at the lipid-protein interface of the human multidrug transporter P-glycoprotein.
Mandal D; Moitra K; Ghosh D; Xia D; Dey S
Biochemistry; 2012 Apr; 51(13):2852-66. PubMed ID: 22360349
[TBL] [Abstract][Full Text] [Related]
20. Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells.
Anuchapreeda S; Leechanachai P; Smith MM; Ambudkar SV; Limtrakul PN
Biochem Pharmacol; 2002 Aug; 64(4):573-82. PubMed ID: 12167476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]